NEW YORK, Nov. 12 - Lynx Therapeutics today said the Ludwig Institute for Cancer Research has asked it to extend a cancer gene-expression collaboration begun in July that relies on the company's MPSS technology.
Terms of the agreement calls for an undisclosed number of LICR branches worldwide to send tissue samples to Lynx for gene-expression studies. Data from this expanded partnership will be "compatible" with gene-expression information that Lynx generated for the National Cancer Institute, the company added.
"The data should allow us to do a lot more than we ever could before with microarrays, SAGE, and ESTs," Andrew Simpson, a senior geneticist with LICR, said in a statement. "We plan to do many more MPSS analyses as soon as possible."
Click here for more information.